Immunic, Inc. (NASDAQ:IMUX) Receives $6.60 Consensus Target Price from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have received a consensus rating of “Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $6.00.

A number of analysts have recently commented on IMUX shares. HC Wainwright cut their target price on Immunic from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Chardan Capital raised Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Roth Mkm initiated coverage on shares of Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, Brookline Capital Acquisition upgraded Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd.

Hedge Funds Weigh In On Immunic

Large investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC acquired a new stake in Immunic in the fourth quarter valued at approximately $2,337,000. Vanguard Group Inc. lifted its position in shares of Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after purchasing an additional 219,957 shares in the last quarter. Laurion Capital Management LP boosted its stake in shares of Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after purchasing an additional 2,000,000 shares during the period. Millennium Management LLC grew its holdings in Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Finally, Focus Partners Wealth grew its holdings in Immunic by 1.5% during the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after purchasing an additional 39,063 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Stock Up 3.9%

IMUX stock opened at $1.06 on Thursday. The stock has a market cap of $138.29 million, a price-to-earnings ratio of -1.51 and a beta of 1.45. The business has a fifty day moving average of $0.71 and a two-hundred day moving average of $0.76. Immunic has a 52-week low of $0.51 and a 52-week high of $1.35.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, sell-side analysts anticipate that Immunic will post -0.94 EPS for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.